Birth Control Linked To Brain Tumors

A massive Danish study just found that some of the most common birth control methods on the market carry a small but real link to brain tumors called meningiomas.

Quick Take

A large Danish registry study found several progestogen-based birth control methods linked to higher meningioma risk.
Injectable medroxyprogesterone showed the strongest signal, with risk roughly four times higher than non-users.
High-dose levonorgestrel IUDs also showed a smaller but statistically significant increase in risk.
Doctors stress the tumor remains extremely rare and often shrinks after stopping the hormone.

What The Danish Study Actually Found

Researchers pulled 25 years of health records from Danish women ages 15 to 59 to study meningioma, a tumor that grows in the tissue covering the brain and spinal cord. The study, published in JAMA Network Open, found that recent use of several progestogen birth control products raised the odds of developing this tumor. The strongest link appeared with injectable medroxyprogesterone, known by the brand name Depo-Provera.

Women using that injection saw roughly a four-fold increase in relative risk compared to women who did not use hormonal birth control, according to outside experts who reviewed the findings. High-dose levonorgestrel IUDs, a hormone-releasing device placed in the uterus, showed a smaller increase. The odds ratio for that device came in at 1.58, meaning a 58 percent higher relative risk among users.

Why This Isn’t The First Warning Sign

This is not a one-off finding. Earlier French, Swedish, and British registry studies already flagged similar progestogen compounds years before this Danish paper landed. A 2023 case-control study found that prolonged use of medrogestone, medroxyprogesterone acetate, and promegestone increased meningioma risk. A separate Swedish study found the risk with injectable medroxyprogesterone climbed even higher among long-term users, with some estimates reaching a five-fold increase.

Combined oral contraceptives containing desogestrel or levonorgestrel have also drawn scrutiny in British Medical Journal research examining large patient databases. The pattern across countries and study designs points to the same handful of high-dose or injectable formulations, not to birth control pills as a broad category. That distinction matters for any woman trying to make sense of her own risk.

How Rare Is Rare, Really

Meningioma remains uncommon even with this added risk. Danish drug regulators described the tumor as “a very rare side effect” of progestogen contraception, based on their own review of the data. Most meningiomas are not cancerous, and many grow slowly enough that doctors simply monitor them instead of operating.

Canadian health reporting on the same Danish findings echoed that caution, noting the overall risk stays “extremely rare” and often fades within a few years after a woman stops the medication. That detail deserves attention because it suggests the tumor risk is not a permanent mark left by past birth control use. It appears tied to active or recent hormone exposure rather than lifetime exposure.

What Doctors Are Telling Patients Now

Medical experts reacting to the study emphasize proportion over panic. The relative risk increase sounds alarming, but the absolute number of women affected stays small given how rare meningioma is in the general population. Doctors at the University of California, San Francisco Brain Tumor Center note that newer research spanning French, American, and Swedish populations consistently shows women using medroxyprogesterone injections face two to six times greater risk than nonusers.

No single study should drive an immediate medication change without a conversation with a prescribing doctor. Women currently using injectable medroxyprogesterone or high-dose hormonal IUDs should ask their physician whether their personal risk factors, family history, or symptoms like persistent headaches or vision changes warrant closer monitoring. Informed choice, not fear, should guide that conversation.

The Bigger Picture On Hormonal Health Research

This finding fits a recurring theme in women’s health research: large government-run health registries in Denmark, Sweden, and France keep surfacing signals that smaller American studies often miss simply due to scale. These countries track prescriptions and diagnoses across entire populations for decades, giving researchers statistical power that United States studies rarely match.

That kind of transparency benefits patients everywhere, even when the news feels unsettling. Women deserve full information about medications they take for years, sometimes decades, of their reproductive lives. This study adds one more data point to a growing body of evidence, and it belongs in every conversation between a woman and her doctor about which contraceptive method fits her body and her risk tolerance best.